An observational study in Frailty, Sarcopenia and COVID-19, sponsored by Methodist Health System. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-10.
Sponsored by Methodist Health System · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 185 studies in Frailty with a site in United States — 50 open to participants now, 62 under way, 1 of them phase 3. Frailty · United States.
Among the 185 studies in Frailty with a site in United States, this one is the 19th largest by planned enrollment of the 42 observational ones that give a count, is one of 19 that started in 2022, is one of 42 observational ones, reaches primary completion later than 38 of the 60 other live ones, and was the 140th registered.
1,284 studies on the registry are indexed under Frailty; 451 are open to participants now.
Browse Frailty studies →50 of the 185 studies in Frailty with a site in United States are open now. Recruiting first, the newest first:
University of Maryland, Baltimore · Sites in United States
Ages 55+
University of California, San Francisco · Sites in United States
Ages 18–75
Longevity Metrics, Inc. · Sites in United States
Ages 18+ · Healthy volunteers
William Brandenburg, MD · Sites in United States
Ages 18+ · Healthy volunteers
Longevity Metrics, Inc. · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 299 Frailty studies recruiting now, 235 (79%) set no upper age limit and 9 (3%) stop at 75 or younger; 7 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
185 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 32 · Phase 3 5 · Phase 4 5
First in 2001; this study’s year is marked. 19 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 208 is close to the median of 225 across 493 observational studies indexed under Frailty.
Median enrollment 42 across the 142 interventional studies, 128 across the 42 observational. Of the 112 that completed or were terminated, 42 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 185 have an industry lead sponsor. The 10 most frequent:
Methodist Health System is the lead sponsor of 170 studies on the registry; 50 are open to participants now.
Methodist Health System has 1 study filed under Frailty — fewer than ten, so there is no comparison to draw.
24 of the studies in Frailty with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05422534Phase 3Vanderbilt University Medical CenterCoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease | 2027-06-20 |
| NCT03675724Mayo ClinicAlleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults | 2026-11 |
| NCT03430037Mayo ClinicAlleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women | 2026-11 |
| NCT07220512Wake Forest University Health SciencesThe Better, Harder, Faster, Stronger Study | 2026-11 |
| NCT05725928The Cleveland ClinicAssisted Ambulation to Improve Health Outcomes for Older Medical Inpatients | 2026-11-30 |
Add all 24 to your calendar (.ics) → With an account.
Among the 185 studies in Frailty with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Frailty is associated with higher rates of morbidity, mortality, and failure to rescue after major surgical procedures. Sarcopenia is degenerative loss of skeletal muscle mass and strength. It is a key component of physical frailty and is associated with poorer post-surgical outcomes due to decreased patient strength and vitality.
This study seeks to examine whether the (COVID-19) pandemic, an ongoing global health crisis that was declared a national emergency by the US Federal Government on March 13, 2020, has exacerbated both frailty and sarcopenia in a population of liver transplant candidates.
Age 18 years and older Underwent pre-transplant frailty assessment (PFA) at MDMC 369 liver transplant candidates who underwent pre-transplant frailty assessments at the Liver Institute at Methodist Dallas from April 1, 2018 to February 28, 2022. The study data will be divided into cohorts: pre-COVID and COVID. Specifically, the pre-COVID period will consist of the dates between April 1st, 2018 and March 12, 2020, while the COVID period will consist of the dates between March 13, 2020 and February 28th, 2022.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This is a single-center, retrospective study that uses de-identified, anonymized patient data. Data from 369 liver transplant candidates who underwent pre-transplant frailty assessments at the Liver Institute at Methodist Dallas from April 1, 2018 to February 28, 2022. The study data will be divided into cohorts: pre-COVID and COVID. Specifically, the pre-COVID period will consist of the dates between April 1st, 2018 and March 12, 2020, while the COVID period will consist of the dates between March 13, 2020 and February 28th, 2022.
To determine the impact of the COVID-19 pandemic on the prevalence of sarcopenia
To determine the impact of the COVID-19 pandemic on the prevalence of sarcopenia and frailty in patients undergoing liver transplant evaluation at Methodist Dallas Medical Center
Time frame: 2 years
To determine the impact of the COVID-19 pandemic on the incidence of sarcopenia
To determine the impact of the COVID-19 pandemic on the incidence of sarcopenia and frailty in patients undergoing liver transplant evaluation at Methodist Dallas Medical Center
Time frame: 2 years
Changes in number of comorbidities between pre- and during/post-pandemic periods
Changes in number of comorbidities between pre- and during/post-pandemic periods
Time frame: 1 year
Changes in type of comorbidities between pre- and during/post-pandemic periods
Changes in type of comorbidities between pre- and during/post-pandemic periods
Time frame: 1 year
Changes in severity of comorbidities between pre- and during/post-pandemic periods
Changes in severity of comorbidities between pre- and during/post-pandemic periods
Time frame: 1 year
Started Apr 2022 (actual). Primary completion is estimated for Apr 2027, 60 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.